FDA urged to boost US access to new and experimental drugs as trials shift to China

The piece highlights that the FDA has taken steps such as launching Operation TrialBlazer and tightening review of foreign clinical data, but argues that further action is required to keep the United States competitive.

It warns that a growing shift of clinical research to China could erode the U.S. biotech lead and reduce American patients' options for experimental treatments.

The regulator recently announced initiatives to accelerate first‑in‑human studies under the broader Operation TrialBlazer program, aiming to retain more trials on U.S. soil.

The author, a physician‑scientist, notes that added procedural layers lengthen timelines for rare disease and cancer trials, pushing patients toward overseas studies where U.S. clinicians have limited enrollment ability.